CLINICAL SIGNIFICANCE OF DETECTION OF EGFR AND KRAS MUTATIONS IN PLASMA/PLEURAL EFFUSION IN PATIENTS WITH ADVANCED NSCLC

被引：0

作者：

Chen, Zhengtang ^{[1
]}

Sun, Jie ^{[1
]}

Ming, Hua ^{[1
]}

Sun, Jianguo ^{[1
]}

Wang, Xinxin ^{[1
]}

Peng, Lina ^{[1
]}

机构：

[1] Third Mil Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

NSCLC; EGFR/KRAS mutation; tyrosine kinase inhibitor; pyrosequencing;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-003

引用

页码：S781 / S782

页数：2

共 50 条

[31] EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer [J].

Linardou, H. ;

Kotoula, V. ;

Kouvatseas, G. ;

Karavasilis, V. ;

Mountzios, G. ;

Samantas, E. ;

Kalogera-Fountzila, A. ;

Televantou, D. ;

Papadopoulou, K. ;

Mavropoulou, X. ;

Daskalaki, E. ;

Zaramboukas, T. ;

Efstratiou, I. ;

Lambaki, S. ;

Rallis, G. ;

Res, E. ;

Syrigos, K. ;

Kosmidis, P. ;

Pectasides, D. ;

Fountzilas, G. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S890-S890

[32] Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients [J].

Marchetti, Antonio ;

Palma, John F. ;

Felicioni, Lara ;

De Pas, Tommaso M. ;

Chiari, Rita ;

Del Grammastro, Maela ;

Filice, Giampaolo ;

Ludovini, Vienna ;

Brandes, Alba A. ;

Chella, Antonio ;

Malorgio, Francesco ;

Guglielmi, Flavio ;

De Tursi, Michele ;

Santoro, Armando ;

Crino, Lucio ;

Buttitta, Fiamma .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) :1437-1443

[33] Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment [J].

Bordi, Paola ;

Tiseo, Marcello ;

Rofi, Eleonora ;

Petrini, Iacopo ;

Restante, Giuliana ;

Danesi, Romano ;

Del Re, Marzia .

CLINICAL LUNG CANCER, 2017, 18 (06) :692-697

[34] Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions [J].

Mayo-de-las-Casas, C. ;

Jordana-Ariza, N. ;

Garzon-Ibanez, M. ;

Balada-Bel, A. ;

Bertran-Alamillo, J. ;

Viteri-Ramirez, S. ;

Reguart, N. ;

Munoz-Quintana, M. A. ;

Lianes-Barragan, P. ;

Camps, C. ;

Jantus, E. ;

Remon-Massip, J. ;

Calabuig, S. ;

Aguiar, D. ;

Gil, M. L. ;

Vinolas, N. ;

Santos-Rodriguez, A. K. ;

Majem, M. ;

Garcia-Pelaez, B. ;

Villatoro, S. ;

Perez-Rosado, A. ;

Monasterio, J. C. ;

Ovalle, E. ;

Catalan, M. J. ;

Campos, R. ;

Morales-Espinosa, D. ;

Martinez-Bueno, A. ;

Gonzalez-Cao, M. ;

Gonzalez, X. ;

Moya-Horno, I. ;

Sosa, A. E. ;

Karachaliou, N. ;

Rosell, R. ;

Molina-Vila, M. A. .

ANNALS OF ONCOLOGY, 2017, 28 (09) :2248-2255

[35] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors [J].

Benesova, Lucie ;

Minarik, Marek ;

Jancarikova, Dana ;

Belsanova, Barbora ;

Pesek, Milos .

ANTICANCER RESEARCH, 2010, 30 (05) :1667-1671

[36] Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy [J].

Fiala, Ondrej ;

Pesek, Milos ;

Finek, Jindrich ;

Benesova, Lucie ;

Bortlicek, Zbynek ;

Minarik, Marek .

ANTICANCER RESEARCH, 2013, 33 (04) :1705-1711

[37] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) [J].

Lee, Ji Yun ;

Xu Qing ;

Wei Xiumin ;

Bai Yali ;

Chi, Sangah ;

Bak, So Hyeon ;

Lee, Ho Yun ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Cho, Eun Kyung ;

Kim, Dong-Wan ;

Kim, Hye Ryun ;

Min, Young Joo ;

Jung, Sin-Ho ;

Park, Keunchil ;

Mao Mao ;

Ahn, Myung-Ju .

ONCOTARGET, 2016, 7 (06) :6984-6993

[38] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients [J].

Wang, Chunsheng ;

Zhao, Kewei ;

Hu, Shanliang ;

Dong, Wei ;

Gong, Yan ;

Li, Minghuan ;

Xie, Conghua .

LUNG CANCER, 2022, 172 :86-93

[39] Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations [J].

Li, Xuefei ;

Cai, Weijing ;

Yang, Guohua ;

Su, Chunxia ;

Ren, Shengxiang ;

Zhao, Chao ;

Hu, Rongjun ;

Chen, Xiaoxia ;

Gao, Guanghui ;

Guo, Zhiwei ;

Li, Wei ;

Zhou, Caicun ;

Hirsch, Fred R. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) :1388-1397

[40] Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy [J].

Alvisi, Maria Francesca ;

Ganzinelli, Monica ;

Linardou, Helena ;

Caiola, Elisa ;

Lo Russo, Giuseppe ;

Cecere, Fabiana Letizia ;

Bettini, Anna Cecilia ;

Psyrri, Amanda ;

Milella, Michele ;

Rulli, Eliana ;

Fabbri, Alessandra ;

De Maglie, Marcella ;

Romanelli, Pierpaolo ;

Murray, Samuel ;

Ndembe, Gloriana ;

Broggini, Massimo ;

Garassino, Marina Chiara ;

Marabese, Mirko .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) :1-10

← 1 2 3 4 5 →